EHA 2018: Consider Ibrutinib-Rituximab (IR) as Standard Therapeutic Option for Waldenström’s Macroglobulinemia
Efficacy of the IR combination superior to that of rituximab alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.